LeMaitre Vascular (NASDAQ:LMAT) Earns Media Impact Rating of 0.08
Media stories about LeMaitre Vascular (NASDAQ:LMAT) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LeMaitre Vascular earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 43.98998864971 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- LeMaitre Vascular, Inc. (LMAT) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Insider Selling: LeMaitre Vascular, Inc. (LMAT) CEO Sells 11,300 Shares of Stock (americanbankingnews.com)
- LeMaitre Vascular, Inc. (LMAT) Chairman Sells $700,770.00 in Stock (americanbankingnews.com)
- LeMaitre Vascular, Inc. (LMAT) Insider Peter R. Gebauer Sells 6,224 Shares (americanbankingnews.com)
- Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 10,000 Shares of Stock (americanbankingnews.com)
LeMaitre Vascular (NASDAQ:LMAT) traded up 0.73% during mid-day trading on Friday, hitting $32.99. 220,949 shares of the stock were exchanged. The firm has a market capitalization of $627.54 million, a price-to-earnings ratio of 47.13 and a beta of 0.65. The company’s 50-day moving average price is $31.03 and its 200 day moving average price is $27.38. LeMaitre Vascular has a 52 week low of $16.80 and a 52 week high of $36.09.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.06. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The firm had revenue of $25.80 million for the quarter, compared to the consensus estimate of $25.42 million. During the same period in the previous year, the firm posted $0.14 EPS. The business’s quarterly revenue was up 15.2% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular will post $0.80 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd will be issued a $0.055 dividend. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.67%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.88%.
LeMaitre Vascular announced that its board has authorized a share repurchase program on Thursday, July 27th that allows the company to repurchase $7.50 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.
Several research firms have issued reports on LMAT. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Friday, April 28th. Stifel Nicolaus restated a “buy” rating and set a $32.00 price target (up from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Benchmark Co. upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, July 28th. Canaccord Genuity restated a “buy” rating and set a $28.00 price target on shares of LeMaitre Vascular in a research report on Thursday, April 27th. Finally, BidaskClub lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $30.17.
COPYRIGHT VIOLATION NOTICE: “LeMaitre Vascular (NASDAQ:LMAT) Earns Media Impact Rating of 0.08” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/lemaitre-vascular-nasdaqlmat-earns-media-impact-rating-of-0-08.html.
In related news, CEO George W. Lemaitre sold 11,300 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $32.79, for a total transaction of $370,527.00. Following the transaction, the chief executive officer now directly owns 3,405,508 shares in the company, valued at approximately $111,666,607.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman George W. Lemaitre sold 58,700 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $33.97, for a total transaction of $1,994,039.00. Following the transaction, the chairman now owns 3,471,808 shares in the company, valued at $117,937,317.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 263,759 shares of company stock worth $8,733,304. Insiders own 23.70% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.